News coverage about Horizon Pharma PLC (NASDAQ:HZNP) has trended somewhat positive this week, AlphaOne Sentiment Analysis reports. AlphaOne, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Horizon Pharma PLC earned a news sentiment score of 0.19 on AlphaOne’s scale. AlphaOne also assigned news stories about the biopharmaceutical company an impact score of 97 out of 100, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Alpha One Sentiment Analysis’s scoring:
- Horizon Pharma (HZNP) Announces Health Canada Approval of PROCYSBI for Treatment of Nephropathic Cystinosis (streetinsider.com)
- Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine … (globenewswire.com)
- Horizon Pharma plc (NASDAQ:HZNP) Trading Up – Short Interest Up by 5.27% (highlightpress.com)
- Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis (finance.yahoo.com)
- Horizon Pharma Ord (HZNP) A Look at Technical Overview (nyhetsbanken.info)
Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up 3.879% during trading on Tuesday, hitting $11.115. The stock had a trading volume of 2,852,891 shares. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $23.44. The firm’s market cap is $1.81 billion. The stock has a 50 day moving average of $11.23 and a 200 day moving average of $14.81.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.04. The firm had revenue of $220.90 million for the quarter, compared to the consensus estimate of $248.71 million. Horizon Pharma PLC had a negative net margin of 21.26% and a positive return on equity of 21.51%. Horizon Pharma PLC’s revenue was up 7.9% on a year-over-year basis. During the same period last year, the business earned $0.34 EPS. On average, equities analysts anticipate that Horizon Pharma PLC will post $0.84 EPS for the current year.
HZNP has been the topic of several recent analyst reports. BMO Capital Markets reiterated a “buy” rating and issued a $24.00 price target on shares of Horizon Pharma PLC in a research note on Wednesday, March 29th. Citigroup Inc. cut their target price on Horizon Pharma PLC from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. Morgan Stanley reaffirmed an “equal weight” rating and set a $20.00 target price on shares of Horizon Pharma PLC in a report on Tuesday, February 28th. Cantor Fitzgerald started coverage on Horizon Pharma PLC in a report on Friday. They set an “overweight” rating and a $13.00 target price on the stock. Finally, ValuEngine downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $20.77.
In other news, Director Michael G. Grey purchased 10,000 shares of Horizon Pharma PLC stock in a transaction that occurred on Wednesday, May 10th. The stock was bought at an average price of $9.48 per share, with a total value of $94,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is owned by company insiders.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.